08/09/23 4:05 PMNasdaq : ADMA earningsADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA (1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss (2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million AdjustedRHEA-AIneutral
08/02/23 7:00 AMNasdaq : ADMA conferencesearningsADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, andRHEA-AIneutral
07/19/23 7:00 AMNasdaq : ADMA fda approvalADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GAADMA Biologics,RHEA-AIneutral
05/10/23 4:05 PMNasdaq : ADMA earningsADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1 ) , Totaling $2.5 Million, Earlier Than Forecasted FY2023 Total Revenue Now Expected to Exceed $220 Million, Increased fromRHEA-AIneutral
05/03/23 7:00 AMNasdaq : ADMA conferencesearningsADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developingRHEA-AIneutral
05/02/23 7:00 AMNasdaq : ADMA ADMA Biologics Announces Amendment to Credit AgreementADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or theRHEA-AIneutral
03/23/23 4:05 PMNasdaq : ADMA earningsADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y Increase FY 2023 Total Revenue Expected to Exceed $210 Million First-Time Positive EBITDA Expected No Later than Second Half of 2023 Conference Call Scheduled for Today at 4:30 p.m.RHEA-AIpositive
03/16/23 7:00 AMNasdaq : ADMA conferencesearningsADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, andRHEA-AIneutral
02/08/23 7:00 AMNasdaq : ADMA fda approvalADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LAADMA Biologics,RHEA-AIvery positive
01/17/23 7:00 AMNasdaq : ADMA ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial GuidanceFourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Year 2021 Full Year 2023 Total Revenues are Expected to be $210RHEA-AIvery positive